PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis
- 14 July 2015
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (17) , 4277-4290
Abstract
Background and Purpose: cAMP plays an important role in the transduction of signalling pathways involved in neuroprotection and immune regulation. Control of the levels of this nucleotide by inhibition of cAMP‐specific PDEs such as PDE7 may affect the pathological processes of neuroinflammatory diseases like multiple sclerosis (MS). In the present study, we evaluated the therapeutic potential of the selective PDE7 inhibitor, TC3.6, in a model of primary progressive multiple sclerosis (PPMS), a rare and severe variant of MS.Experimental Approach: Theiler's murine encephalomyelitis virus‐induced demyelinated disease (TMEV‐IDD) is one of the models used to validate the therapeutic efficacy of new drugs in MS. As recent studies have analysed the effect of PDE7 inhibitors in the EAE model of MS, here the TMEV‐IDD model was used to test their efficacy in a progressive variant of MS. Mice were subjected to two protocols of TC3.6 administration: on the pre‐symptomatic phase and once the disease was established.Key Results: Treatment with TC3.6 ameliorated the disease course and improved motor deficits of infected mice. This was associated with down‐regulation of microglial activation and reduced cellular infiltrates. Decreased expression of pro‐inflammatory mediators such as COX‐2 and the cytokines, IL‐1β, TNF‐α, IFN‐γ and IL‐6 in the spinal cord of TMEV‐infected mice was also observed after TC3.6 administration.Conclusion: These findings support the importance of PDE7 inhibitors, and specifically TC3.6, as a novel class of agents with therapeutic potential for PPMS. Preclinical studies are needed to determine whether their effects translate into durable clinical benefits.Keywords
Funding Information
- Ministry of Science and Innovation (SAF2010-16365, SAF2012-33600)
- Instituto de Salud Carlos III (RD07/0060/0015, RD07/0060/0010)
- Fundación Española para la Ciencia y la Tecnología (FECYT) (FCT-09-INC-0367)
- CSIC
This publication has 56 references indexed in Scilit:
- Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's diseaseNeurobiology of Aging, 2013
- Mouse Models of Multiple Sclerosis: Experimental Autoimmune Encephalomyelitis and Theiler’s Virus-Induced Demyelinating Disease2012
- Modulation of T cell immune functions by the prostaglandin E2 – cAMP pathway in chronic inflammatory statesBritish Journal of Pharmacology, 2012
- Phosphodiesterase 7 Inhibition Preserves Dopaminergic Neurons in Cellular and Rodent Models of Parkinson DiseasePLOS ONE, 2011
- Theiler's virus infection: Pathophysiology of demyelination and neurodegenerationPathophysiology, 2011
- PDE 7 Inhibitors: New Potential Drugs for the Therapy of Spinal Cord InjuryPLOS ONE, 2011
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Neuropathogenesis of Theiler’s Murine Encephalomyelitis Virus Infection, An Animal Model for Multiple SclerosisJournal of Neuroimmune Pharmacology, 2009
- Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosisGlia, 2008